Posts By: admin

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec a iaculis ipsum. Etiam varius facilisis libero, nec rutrum eros eleifend ut.

Stevenage, UK, September 27th 2017 – NeRRe Therapeutics, which is developing a unique portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity, has appointed Andrew Kay as Chairman of the Board. Mr. Kay, who has extensive product development and commercial experience across the pharma and biotechnology sectors, takes over from Dr Kaasim Mahmood of Advent, who remains on the Board. Following the demerger of KaNDy Therapeutics, announced today, NeRRe Therapeutics is primarily focused on its lead product orvepitant, which is in a multinational Phase IIb trial for chronic refractory cough.

Read More

First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company

Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions and is backed by internationally recognised life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors.
NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal vasomotor symptoms (PMVMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd a separate legal entity.

Read More

NeRRe Therapeutics, is pleased to announce the appointment of Dr Steve Pawsey as Chief Medical Officer. Dr Pawsey, an anaesthetist by training, has extensive experience in the global pharmaceutical and biotechnology sector, having worked in clinical development roles for over 20 years. He will lead the progress of NeRRe’s two lead NK receptor antagonists, orvepitant and NT-814, towards late-stage clinical development, for which activity an oversubscribed £23m fundraising was recently announced.

Read More

New investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed join existing investors Advent Life Sciences and Novo A/S

Stevenage, UK, 5th January 2017 – NeRRe Therapeutics (‘NeRRe’), a clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity, announced it has raised £23 million in an oversubscribed Series B financing round.

The funds will be used by NeRRe to generate Phase 2 data on orvepitant, its lead oral NK-1 antagonist candidate as a potential new treatment for a common, chronic respiratory condition; and to advance NT-814, a dual NK-1,3 antagonist, into Phase 2 trials as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

The financing round involved a syndicate of leading transatlantic life sciences investors led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed. Existing investors, Advent Life Sciences and Novo A/S also participated.

Read More

Stevenage, UK, 23 September 2015.

NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr1 is joining the company as CEO at the beginning of October. Mary has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles at the pharmaceutical company GSK and predecessor companies, predominantly in the speciality and orphan drug areas. She has also been appointed an Operating Partner at Advent Life Sciences, one of NeRRe’s investors.

Read More

London, UK, 19th December 2012.

NeRRe Therapeutics Ltd, is launched today to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (“GSK”).

NeRRe has raised £11.5 million ($18.4 million) in Series A financing to support the progression of these molecules into clinical studies in diseases for which there is substantial unmet medical need.

Read More